Velasof is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin Velasof (Velpatasvir 100mg & Sofosbuvir 400mg) Tablets should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

What is Velasof?

VELASOF is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: a. without cirrhosis or with compensated cirrhosis b. with advanced cirrhosis (decompensated) in combination with ribavirin. VELASOF contains the two medicines: sofosbuvir and velpatasvir.

Where can I buy Velasof?

Indian Pharma Network (IPN) is a supplier & wholesaler. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience. IPN is your facilitator under Patient Assistance Programs.

Please contact +91 9811747774 for
Velasof cost in India or Velpatasvir & Sofosbuvir price in in India.
VELASOF (Velpatasvir 100mg & Sofosbuvir 400mg)

Click To Chat

Get In Touch

Velasof suppliers & wholesalers in India

Head Office of Indian Pharma Network (IPN) is in New Delhi, INDIA.
For Indian Patients VELASOF can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India.
For overseas patient VELASOF or Velpatasvir & Sofosbuvir brands in India can be also made available to overseas patients, doctors and hospitals. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

Tablets: Velpatasvir 100mg & Sofosbuvir 400mg


FDA News Release

Hetero Healthcare launches combination drug for Hepatitis-C in India
Fri, May 12 2017. 07 59 AM IST